Clinical Trials Browser

Recruiting × anlotinib × Gastrointestinal × Clear all

NCT06662006 2026-02-06

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06767813 2025-09-19

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04278222 2024-07-10

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05229003 2024-07-03

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06354530 2024-04-09

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2/3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06051851 2023-09-25

RCT-PAAG

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic